Bayer/€BAYN
1D1W1MYTD1Y5YMAX
Capital at risk
About Bayer
Bayer AG, operating under the ticker BAYN, is a global enterprise with core competencies in the life sciences fields of healthcare and agriculture. Founded in 1863, the company is headquartered in Leverkusen, Germany, and operates in several sectors, including Pharmaceuticals, Consumer Health, Crop Science, and Animal Health. Bayer is known for developing new molecules for use in innovative products and solutions to improve the health of humans, animals, and plants.
- Ticker
- €BAYN
- Sector
- Health
- Primary listing
- XETRA
- Employees
- 87,830
- Headquarters
- Leverkusen, Germany
- Website
- www.bayer.com
Bayer Metrics
BasicAdvanced
€49B
-
-€1.77
0.83
€0.11
0.22%
Price and volume
Market cap
€49B
Beta
0.83
52-week high
€53.86
52-week low
€25.78
Average daily volume
2M
Dividend rate
€0.11
Financial strength
Current ratio
1.043
Quick ratio
0.671
Long term debt to equity
1.049
Total debt to equity
1.294
Interest coverage (TTM)
2.71%
Profitability
EBITDA (TTM)
10,133
Gross margin (TTM)
60.46%
Net profit margin (TTM)
-3.83%
Operating margin (TTM)
11.93%
Effective tax rate (TTM)
-40.07%
Revenue per employee (TTM)
€520,000
Management effectiveness
Return on assets (TTM)
3.18%
Return on equity (TTM)
-5.69%
Valuation
Price to revenue (TTM)
1.069
Price to book
1.65
Price to tangible book (TTM)
-2.46
Price to free cash flow (TTM)
23.338
Free cash flow yield (TTM)
4.28%
Free cash flow per share (TTM)
2.115
Dividend yield (TTM)
0.22%
Forward dividend yield
0.22%
Growth
Revenue change (TTM)
-1.73%
Earnings per share change (TTM)
-49.16%
3-year revenue growth (CAGR)
-2.34%
10-year revenue growth (CAGR)
1.23%
3-year earnings per share growth (CAGR)
6.37%
10-year earnings per share growth (CAGR)
-10.63%
3-year dividend per share growth (CAGR)
-64.21%
10-year dividend per share growth (CAGR)
-26.83%
What the Analysts think about Bayer
Analyst ratings (Buy, Hold, Sell) for Bayer stock.
Analyst projections of the future price of Bayer stock.
Bulls say / Bears say
Bayer’s Q2 2026 operating performance improved on an adjusted basis, with sales up 2.2% and EBITDA before special items up 1.9%; Crop Science EBITDA rose 30.2%, supporting the profitability-recovery thesis. (Bayer)
The FDA granted accelerated approval for sevabertinib as a first-line treatment for HER2-mutant non-small-cell lung cancer; the therapy posted a 75% objective response rate in the supporting cohort, creating a potentially meaningful new Pharmaceuticals growth driver. (Bayer)
The U.S. Supreme Court blocked thousands of state-court Roundup failure-to-warn lawsuits, potentially reducing Bayer’s long-term litigation overhang and improving visibility around the Monsanto liabilities. (Reuters)
Core earnings per share fell 16.7% year over year in Q2 2026, while free cash flow was negative €0.4 billion and net financial debt reached €33.6 billion, highlighting continued balance-sheet pressure. (Bayer)
Bayer still faces substantial Roundup exposure: its proposed $7.25 billion settlement is awaiting Missouri court approval, leaving the company exposed to further legal uncertainty and significant cash outflows. (Reuters)
Profitability remains uneven beyond Crop Science: Q2 Pharmaceuticals EBITDA declined 3.6% and Consumer Health EBITDA also fell 3.6%, suggesting that the turnaround is not yet broad-based. (Bayer)
Data summarised monthly by Lightyear AI. Last updated on 14 Sept 2026.
Bayer Financial Performance
Revenues and expenses
Bayer Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing Bayer
AllEURGBPUSD
Fund name | Fund size | €BAYN weighting |
|---|---|---|
iShares Edge MSCI Europe Value Factor€CEMS | €2.6B | 3.28% |
iShares Edge MSCI Europe Value Factor£IEFV | £2.2B | 3.28% |
iShares Dax ESG€EXIA | €127M | 3.20% |
iShares MSCI Europe Health Care Sector€ESIH | €863M | 3.09% |
iShares MSCI Europe Health Care Sector£ESIH | £741M | 3.09% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.